metricas
covid
Buscar en
Hipertensión y Riesgo Vascular
Toda la web
Inicio Hipertensión y Riesgo Vascular Albuminuria and cardiovascular risk
Journal Information
Vol. 40. Issue 3.
Pages 137-144 (July - September 2023)
Share
Share
Download PDF
More article options
Visits
23
Vol. 40. Issue 3.
Pages 137-144 (July - September 2023)
Review
Albuminuria and cardiovascular risk
Albuminuria y riesgo cardiovascular
Visits
23
D.H. Rigoa, P.M. Jiménezb, M. Oriasc,
Corresponding author
marcelo.orias@gmail.com

Corresponding author.
a Nephrology Service, Sanatorio Allende, Córdoba, Argentina
b Nephrology Service, Hospital Marcial Vicente Quiroga, San Juan, Argentina
c Yale University, Department Internal Medicine, Sanatorio Allende, Córdoba, Argentina
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Albuminuria stage in studies with SGLT-2 inhibitors.
Abstract

Cardiovascular risk (CVR) estimation is a fundamental tool for guiding therapy. Albuminuria indicates target organ damage in an accessible, economic and non-invasive manner. Improves high-risk patient identification, especially in chronic kidney disease (CKD) and diabetes mellitus (DM). In addition, anti-albuminuric treatments may improve CVR. This would position albuminuria as a guide and therapeutic objective. Although the capacity of albuminuria as an epidemiological CVR marker in specific populations (hypertension, CKD, DM) is accepted, its profile as a risk marker in the general population and as a therapeutic target is controversial. There is ambiguous evidence regarding its predictive capacity, added to the fact that treatments such as SLGT2 blockers reduce CVR events regardless of albuminuria presence or magnitude.

This review analyzes the available evidence on albuminuria as a CVR marker, a treatment goal and therapeutic guide.

Keywords:
Proteinuria
Cardiovascular risk
Albuminuria
Chronic kidney disease
Resumen

La estimación de riesgo cardiovascular (RCV) es una herramienta fundamental para dirigir la terapéutica. Albuminuria indica daño en órgano blanco de manera accesible, económica y no invasiva. Mejora la identificación de pacientes de alto riesgo, especialmente en enfermedad renal crónica (ERC) y diabetes mellitus (DM). Además, tratamientos antialbuminúricos mejorarían el RCV y la ocurrencia de eventos. Esto posicionaría a la albuminuria como guía y objetivo terapéutico. Si bien la capacidad de albuminuria como marcador epidemiológico de RCV en poblaciones específicas es aceptado, su perfil de marcador de riesgo en población general y como objetivo terapéutico es controvertido. Existe evidencia contrapuesta respecto a su capacidad de predicción, sumado a que tratamientos como los bloqueadores SGLT2 reducen eventos CV independientemente de la presencia y/o magnitud de albuminuria.

En esta revisión se analiza la evidencia disponible sobre albuminuria como marcador de RCV, como objetivo de tratamiento y como guía terapéutica.

Palabras clave:
Proteinuria
Riesgo cardiovascular
Albuminuria
Enfermedad renal crónica

Article

These are the options to access the full texts of the publication Hipertensión y Riesgo Vascular
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Hipertensión y Riesgo Vascular

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos